1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,700 | 6,200 | 09:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst | 1 | Benzinga.com | ||
| EUPRAXIA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Mo | William Blair initiates Eupraxia stock with Outperform rating | 1 | Investing.com | ||
| Mo | William Blair startet Coverage für Eupraxia mit "Outperform" | - | Investing.com Deutsch | ||
| 17.03. | Eupraxia Pharmaceuticals Inc: Eupraxia posts 24-week data in high-dose Resolve cohort | 1 | Stockwatch | ||
| 17.03. | Stocks in Play: Eupraxia Pharmaceuticals Inc. | - | Baystreet.ca | ||
| 17.03. | H.C. Wainwright cuts Eupraxia Pharmaceuticals price target on higher costs | 1 | Investing.com | ||
| 17.03. | Eupraxia reports symptom improvement in eosinophilic esophagitis trial | 1 | Investing.com | ||
| 17.03. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.03. | Eupraxia Pharmaceuticals reports Q4 results | 4 | Seeking Alpha | ||
| 13.03. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results | 468 | GlobeNewswire (Europe) | VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging... ► Artikel lesen | |
| 06.03. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 23.02. | Bloom Burton initiates Eupraxia stock with buy rating on EoE drug | 1 | Investing.com | ||
| 21.02. | Eupraxia Pharmaceuticals Inc: Eupraxia Pharmaceuticals to list 6,428,574 more shares | 1 | Stockwatch | ||
| 21.02. | Eupraxia Pharmaceuticals Inc: Eupraxia Pharmaceuticals closes $63.2M (U.S.) offering | 1 | Stockwatch | ||
| 20.02. | Eupraxia-Aktie legt nach Kapitalerhöhung über 63 Mio. US-Dollar zu | 1 | Investing.com Deutsch | ||
| 20.02. | Eupraxia Pharmaceuticals closes $63.2M public offering | 1 | Investing.com | ||
| 20.02. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option | 211 | GlobeNewswire (Europe) | VICTORIA, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging... ► Artikel lesen | |
| 19.02. | Eupraxia Pharmaceuticals Inc: Eupraxia prices $55-million (U.S.) public offering | 1 | Stockwatch | ||
| 19.02. | Eupraxia Pharmaceuticals stock falls after pricing $55M public offering | 1 | Seeking Alpha | ||
| 19.02. | Eupraxia Pharmaceuticals prices $55 million public offering | 3 | Investing.com |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 1,400 | +3,70 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,176 | -1,49 % | Canaccord reiterates Pacific Biosciences stock rating on new chemistry | ||
| EXACT SCIENCES | 90,94 | +0,22 % | XFRA EXK: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILEXACT SCIEN. DL-... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,706 | +0,16 % | Arbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update | Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement for infringement of lipid nanoparticle (LNP) delivery... ► Artikel lesen | |
| XOMA ROYALTY | 25,000 | 0,00 % | XOMA Royalty Corporation: XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements | Portfolio receipts: • Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increased 9% with royalties... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,604 | +4,84 % | Cardiff Oncology, Inc.: Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer | ||
| IMMUNIC | 1,054 | -2,23 % | Immunic garners new Buy at Guggenheim on lead asset | ||
| IOVANCE BIOTHERAPEUTICS | 3,160 | +0,99 % | Iovance Biotherapeutics: Aufsichtsratsmitglied Wendy Yarno kündigt Rücktritt an | ||
| GUARDANT HEALTH | 74,30 | +3,14 % | Cathie Wood's ARK sells Guardant Health stock, buys Arcturus Therapeutics | ||
| CYTOKINETICS | 51,50 | -0,96 % | Mizuho raises Cytokinetics stock price target to $100 on IP extension | ||
| COHERUS ONCOLOGY | 1,520 | +3,61 % | Coherus Oncology, Inc.: Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 - - Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 - - $172.1... ► Artikel lesen | |
| CURIS | 0,630 | +1,61 % | Curis, Inc.: Curis Provides Fourth Quarter 2025 Business Update | Management to host conference call today at 4:30 p.m. ET
LEXINGTON, Mass., March 19, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused... ► Artikel lesen | |
| FATE THERAPEUTICS | 0,982 | -0,53 % | Mizuho bestätigt "Outperform"-Rating für Fate Therapeutics nach Studienfortschritten | ||
| AGENUS | 3,200 | +4,58 % | Agenus Inc.: Agenus meldet Abschluss einer strategischen Kooperationsvereinbarung mit Zydus Lifesciences im Wert von 141 Millionen US-Dollar zur Weiterentwicklung von BOT+BAL und Stärkung der Produktionskapazitäten in den USA | Agenus Inc. (Nasdaq: AGEN), ein führendes Unternehmen auf dem Gebiet der Immunonkologie, gab heute den Abschluss seiner bereits angekündigten strategischen Zusammenarbeit mit Zydus Lifesciences... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 3,733 | -0,05 % | ROCKET PHARMACEUTICALS, INC. - 8-K, Current Report |
Das Unternehmen EUPRAXIA PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,88 % bei einem Aktienkurs von 5,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EUPRAXIA PHARMACEUTICALS INC finden Sie auf Wallstreet Online.